Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Xia Cao, Junki Maruyama, Heyue Zhou, Yanwen Fu, Lisa Kerwin, Colin Powers, Rachel A. Sattler, John T. Manning, Alok Singh, Reyna Lim, Laura D. Healy, Sachi Johnson, Elizabeth Paz Cabral, Donghui Li, Lucy Lu, Arthur Ledesma, Daniel Lee, Susan Richards, Laura Rivero-Nava, Yan LiWeiqun Shen, Karen Stegman, Benjamin Blair, Shinji Urata, Magumi Kishimoto-Urata, Jamie Ko, Na Du, Kyndal Morais, Kate Lawrence, Ianne Rivera, Chin I. Pai, Damien Bresson, Mark Brunswick, Yanliang Zhang, Henry Ji, Slobodan Paessler, Robert D. Allen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

Original languageEnglish (US)
Article number15517
JournalScientific reports
Issue number1
StatePublished - Dec 2022

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies'. Together they form a unique fingerprint.

Cite this